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The Ca2þ-sensing receptor (CaSR) plays an important role in regulating vascular tone. In the present study,
we investigated the positive effects of the vagal neurotransmitter acetylcholine by suppressing CaSR
activation in mesenteric arteries exposed to hypoxia/reoxygenation (H/R). The artery rings were exposed
to a modiﬁed ‘ischemia mimetic’ solution and an anaerobic environment to simulate an H/R model. Our
results showed that acetylcholine (106 mol/L) signiﬁcantly reduced the contractions induced by KCl and
phenylephrine and enhanced the endothelium-dependent relaxation induced by acetylcholine. Addi-
tionally, acetylcholine reduced CaSRmRNA expression and activitywhen the ringswere subjected to 4 h of
hypoxia and 12 h of reoxygenation. Notably, the CaSR antagonist NPS2143 signiﬁcantly reduced the
contractions but did not improve the endothelium-dependent relaxation. When a contractile response
was achievedwith extracellular Ca2þ, both acetylcholine andNPS2143 reversed theH/R-induced abnormal
vascular vasoconstriction, and acetylcholine reversed the calcimimetic R568-induced abnormal vascular
vasoconstriction in the artery rings. In conclusion, this study suggests that acetylcholine ameliorates the
dysfunctional vasoconstriction of the arteries after H/R, most likely by decreasing CaSR expression and
activity, thereby inhibiting the increase in intracellular calcium concentration. Our ﬁndings may be
indicative of a novel mechanism underlying ACh-induced vascular protection.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
In experimental models and clinical cases, blood vessels are very
vulnerable to the deleterious consequences of cardiovascular dis-
ease, particularly ischemia/reperfusion (I/R). I/R affects endothelial
function and vasomotricity, including the production of nitric ox-
ide, relaxation/contraction of vascular smooth muscle cells, and
expression of inﬂammatory factors (1, 2). The intracellular calcium
concentration ([Ca2þ]i) plays a key role in vasomotricity, and it can
be increased via activation of the speciﬁc inositol 1,4,5-
trisphosphate receptor (IP3R) when the calcium-sensing receptor
(CaSR) is activated (3). CaSR belongs to the G protein-coupleda West Road, Department of
Medicine, Xi'an 710061, PR
. Sun), zwj@mail.xjtu.edu.cn
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).receptor family that was ﬁrst identiﬁed by Brown et al. (4) CaSR is
widely expressed in the cardiovascular system and plays important
roles in cardiac hypertrophy, vascular calciﬁcation, and hyperten-
sion (5,6). Gou et al. reported that acute myocardial infarction and
atherosclerosis can activate CaSR in the heart (7). Li et al. reported
that CaSR was related to the regulation of pulmonary artery tension
by increasing [Ca2þ]i via the G-protein/phospholipase C/IP3R
pathway (8). However, it is unknownwhether CaSR is involved in I/
R-induced vasomotor dysfunction.
The parasympathetic system and the sympathetic system are
sub-divisions of the autonomic nervous system. The action of the
parasympathetic system has been well studied. Normally, the ac-
tivities of the sympathetic and parasympathetic systems are in
dynamic balance. However, in disease states, particularly in car-
diovascular disease, increased sympathetic nervous system activity
and decreased parasympathetic activity are common (9). Vagal
stimulation and the vagal neurotransmitter acetylcholine (ACh) are
used for the prevention and treatment of ventricular ﬁbrillation,
ventricular tachycardia, and vascular endothelial dysfunction innese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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mechanism of the vagus nerve has not been fully deﬁned. Addi-
tionally, little information is available regarding the relationship
between ACh and CaSR.
Therefore, the aims of the present study were to examine the
effects of ACh on mesenteric arteries exposed to hypoxia/reox-
ygenation (H/R) and to determine the possible relationship be-
tween ACh and CaSR using a suitable and reliable in vitro model of
vascular H/R.
2. Materials and methods
2.1. Animal care
The adult male SpragueeDawley rats (180e200 g) used in these
experiments were provided by the Experimental Animal Center of
Xi'an Jiaotong University. The experimental methods were
approved by the Animal Ethics Committee of Xi'an Jiaotong Uni-
versity. The rats were kept in a pathogen-free animal breeding
roommaintained at 24 C with a 12-h day/night cycle and given ad
libitum access to water and standard rat chow.
2.2. Chemicals and agents
ACh, phenylephrine (PE) and sodium nitroprusside (SNP) were
obtained from Sigma. The LDH and CK assay kits were obtained
from the Nanjing Jiancheng Bioengineering Institute (Nanjing,
China). The following antibodies were used in the Western blot
analysis: rabbit polyclonal anti-CaSR and rabbit polyclonal anti-p-
CaSR(Thr888) (Signalway Antibody, Inc., Pearland, TX, USA). Calci-
mimetic R568 hydrochloride and the CaSR antagonist NPS2143
hydrochloride were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The drug concentrations are expressed as the
ﬁnal molar concentration within the organ chamber.
2.3. Experimental protocol
The mesenteric artery rings were randomly assigned to the
following experimental groups (n ¼ 8 per group): the control
group, in which rings were incubated in a normoxic incubator at
37 C with DMEM; the ACh group, in which ACh (106 mol/L) was
administered 15min before normoxic incubation; the H/R group, inFig. 1. Experimental protocol. Black boxes indicate periods of hypoxia induced by a modiﬁed
reoxygenation, and gray boxes indicate periods of R568 intervention. The H/R protocol consi
normoxic culture with DMEM; the ACh þ H/R protocol consisted of a 15-min pretreatment p
of reoxygenation; the control and ACh protocols consisted of routine culture at 37 C with AC
before initiation of the H/R protocol.which rings underwent 4 h of hypoxic culture with modiﬁed
‘ischemia mimetic’ solution and 12 h of normoxic culture with
DMEM; the H/R þ ACh group, in which ACh pretreatment was
started 15 min before hypoxia and continued for 4 h of hypoxia and
12 h of reoxygenation; and the antagonist/agonist groups, in which
rings were treated with the CaSR activator R568 (1 mmol/L) or the
CaSR inhibitor NPS2143 (10 mmol/L) 30 min before initiation of the
H/R protocol (Fig. 1).2.4. In vitro vascular H/R
The mesenteric artery rings were prepared as 1e2-mm-long
cylindrical segments and were quickly moved to a dish ﬁlled with
oxygenated Krebs solution (in mmol/L: NaCl: 119; KCl: 4.7; MgCl2:
1; CaCl2: 2.5; NaHCO3: 25; KH2PO4: 1.2; D-glucose: 11). The detailed
method for this procedure was described previously (13). The rings
were assigned to receive 2, 4, 8, or 12 h of ischemia using amodiﬁed
‘ischemia mimetic’ solution (in mmol/L: NaCl: 135; KCl: 8; MgCl2:
0.5; CaCl2: 1.8; NaH2PO4: 0.33; HEPES: 5.0; Naþ-lactate: 20; pH
6.80; bubbled with 100% N2 for more than 45 min before the
experiment was started to reduce the oxygen tension by 75%) in a
hypoxic environment. Using an anaerobic incubation bag, the rings
were incubated in 24-well, ﬂat-bottom culture plates (one sample
per well) with the modiﬁed ‘ischemia mimetic’ solution. The bag
was ﬂushed with humidiﬁed 93% N2: 5% CO2: 2% O2 at 37 C. After
incubation under ischemic conditions, the medium was replaced
with Dulbecco's modiﬁed Eagle's medium (DMEM) containing L-
glutamine (584 mg/L) and supplemented with penicillin (100 U/
mL) and streptomycin (100 mg/mL). Then, the rings were moved to
a normoxic incubator (95% air: 5% CO2), followed by 2, 6, 12, 18, or
24 h of reperfusion.2.5. Vascular functional studies
The isometric tension of the prepared artery rings was contin-
uously recorded using a Tai Meng BL-420F biotic signal collection
and analysis system (Chengdu, China). The complete experimental
details can be found in our previously published paper (13). The
contractile capacity of the artery rings was tested by exposure to a
high-Kþ Krebs solution (60 mmol/L KCl) prepared by substituting
NaCl with an equimolar amount of KCl.‘ischemia mimetic’ solution and a hypoxic environment, open boxes indicate periods of
sted of 4 h of hypoxic culture with the modiﬁed ‘ischemia mimetic’ solution and 12 h of
eriod with ACh (106 mol/L) before hypoxia and continued with 4 h of hypoxia and 12 h
h or medium; and the antagonist/agonist protocol consisted of an intervention 30 min
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The culture media of the mesenteric artery samples were
collected. The activities of lactate dehydrogenase (LDH) and crea-
tine kinase (CK), as indicators of cell cytotoxicity, were spectro-
photometrically determined in supernatants of the culture media
using commercially available assay kits.
2.7. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the vascular tissue using the
RNAiso Plus reagent (TaKaRa Biotechnology, Dalian, China) ac-
cording to the manufacturer's instructions. The RNA concentration
was determined by measuring the optical density at 260 nm cDNA
was prepared by reverse transcription of 500 ng of total RNA at
42 C for 15 min using the PrimeScript™ RT reagent kit (TaKaRa
Biotechnology). The PCR system contained 1 mL of template cDNA,
0.8 mL of forward primer, 0.8 mL of reverse primer, 10 mL of 2  Taq
MasterMix (CWBIO, Beijing, China), and 7.4 mL of RNase free
dH2Owater to obtain a total volume of 20 mL. The reaction mixture
was ampliﬁed for 36 cycles. The following primers were used: CaSR
forward, 50-GCGTCCTCCTGGTATTTGAA-30; CaSR reverse, 50-
TGAAGGTGCAGAGGAAAACC-30; glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) forward, 50-GGCACAGTCAAGGCTGAGAATG-
30; and GAPDH reverse, 50-ATGGTGGTGAAGACGCCAGTA-30 (Gen-
Script, Nanjing, China).
The PCR products were separated by electrophoresis (80 V,
60 min) on a 1.8% agarose gel that contained ethidium bromide and
visualized under ultraviolet illumination. The intensity of each
band was assessed by a JS-380C image analysis scanning system
(Peiqing, China), and densitometry was used to assess the quantity
relative to GAPDH.
2.8. Western blotting
The vascular tissues were prepared for immunoblotting as
described previously (13). Protein concentration was quantiﬁed
using the bicinchoninic acid (BCA) protein assay (Beyotime
Biotech). Proteins (30 mg/lane) were separated by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis and then elec-
trotransferred to a polyvinylidene diﬂuoride membrane. Nonspe-
ciﬁc binding to the membrane was blocked with 3% bovine serum
albumin for 1 h at room temperature. The membrane was then
incubated with the primary antibodies (CaSR, 1:500; p-CaSR(Thr888),
1:500; and GAPDH, 1:5000) in 5% TBST at 4 C overnight. After
washing the membranes 7 times with TBST for 5 min each wash,
the blots were incubated with horseradish-peroxidase-linked sec-
ondary antibody (1:5000; Cowin Biotech, Beijing, China) for 1 h at
room temperature. After washing, the protein bands were visual-
ized using the ECL-Plus reagent (Pierce, Rockford, IL, USA) and
quantiﬁed by scanning densitometry.
2.9. Calculations and statistical analysis
The data are expressed as the mean ± SEM. The contractile re-
sponses in each ring were determined based on the percentage of
the contraction induced by 60 mmol/L Kþ, and the relaxant re-
sponses in each ring were determined based on the percentage
reduction of the PE (105 mol/L)-induced maximum contraction.
The maximum effect (Emax) represents the maximum contraction
induced by an agonist. The potency of the agonist is expressed as
pD2 (log10EC50), where the EC50 is the agonist concentration
causing 50% of the maximal response. Statistical analyses were
performed by one-way analysis of variance (ANOVA) followed by
Tukey's post-hoc test for multiple comparisons. The level ofsigniﬁcance was set at a two-tailed P < 0.05. All ﬁgures were pre-
pared using GraphPad Prism 5.0 (San Diego, CA, USA).
3. Results
3.1. Effect of ACh on CK and LDH activity in mesenteric arteries
exposed to H/R
The activities of CK and LDH in culturemedia supernatants were
determined, as shown in Fig. 2A to D. Compared with the control
group culture medium, culture medium from the H/R group had
higher levels of CK and LDH, which are indexes of structural dam-
age. The rings subjected to 4 h of ‘ischemia’ and 12 h of ‘reperfusion’
showed marked increases in the release of CK (Fig. 2A: hypoxia 4 h,
0.143 ± 0.03 U/mL; Fig. 2C: reoxygenation 12 h, 0.121 ± 0.02 U/mL)
and LDH (Fig. 2B: hypoxia 4 h, 1.76 ± 0.92 U/mL; Fig. 2D: reox-
ygenation 12 h, 1.63 ± 0.60 U/mL; P < 0.05, P < 0.01 vs. control
group, n ¼ 8). Thus, further experiments were performed using an
‘ischemia’ time of 4 h and a ‘reperfusion’ time of 12 h.
ACh was used to treat the rat mesenteric arteries that were
exposed to H/R. We assessed the effect of ACh (109e105 mol/L)
on the CK and LDH levels of culture media supernatants using the
previously described kits. As shown in Fig. 2 E and F, ACh
(107e105 mol/L) signiﬁcantly decreased the vascular CK and LDH
levels. These results suggested that ACh was capable of reducing H/
R injury in the mesenteric artery. For the remainder of the study,
106 mol/L ACh was used.
3.2. Effect of ACh pretreatment on concentration-response
contractile curves for KCl and PE
To examine the effects of ACh pretreatment on arterial function,
concentration-response curves were constructed for KCl and PE in
the endothelium-intact mesenteric artery rings. The Emax values
induced by KCl and PE were signiﬁcantly higher in the H/R group
compared with the control group (125% ± 5% vs. 103% ± 7% for KCL
and 129% ± 8% vs. 81% ± 12% for PE, respectively, P < 0.01; n ¼ 8).
The Emax valuewas signiﬁcantly decreased in the ACh-pretreatment
group compared with the H/R group (107% ± 5% for KCl and
103% ± 11% for PE; P < 0.05; n ¼ 8; Fig. 3A and B). No signiﬁcant
differences were found between the ACh group and the control
group (104% ± 5% for KCl and 98% ± 11% for PE versus the control
group; P > 0.05).
The concentration-response curves for KCl and PE were shifted
to the left in the H/R groups compared with the respective control
groups. The pD2 values for KCl and PE in the H/Rmodel groupswere
1.83 ± 0.06 and 7.49 ± 0.10, respectively, and the values in the
control groups were 1.59 ± 0.05 and 7.04 ± 0.12, respectively
(P < 0.05, P < 0.01). ACh inhibited the contraction induced by KCl
and PE and also shifted the concentration-response curves toward
the right (pD2 values: 1.64 ± 0.03 and 6.89 ± 0.15, respectively;
P < 0.05, P < 0.01; n ¼ 8). The pD2 values for KCl and PE were not
affected by ACh in the untreated control group (1.57 ± 0.04 and
6.90 ± 0.25, respectively; n ¼ 8).
3.3. Effect of ACh pretreatment on concentration-response
vasodilation curves for ACh and SNP
Vasodilation responses were induced by the endothelium-
dependent vasodilator ACh and the endothelium-independent
vasodilator SNP after pre-constriction with PE (105 mol/L). As
shown in Fig. 4A, the maximum ACh-induced relaxation response
was signiﬁcantly impaired in the H/R group compared with the
control group (57% ± 8% vs. 83% ± 9%, respectively; P < 0.05; n ¼ 8).
Themaximum relaxation in response to ACh inmesenteric vascular
Fig. 2. The levels of LDH and CK in the modiﬁed ‘ischemia mimetic’ solution and DMEM, which were used to culture the mesenteric artery samples. (A and B) Levels of CK and LDH
in the control samples and in samples exposed to hypoxia for 2, 4, 8, or 16 h. (C and D) Levels of CK and LDH in control samples and in samples exposed to hypoxia for 4 h followed
by reoxygenation for 2, 6, 12, 18, or 24 h. (E and F) Effects of ACh on the CK and LDH levels in culture media supernatants. The data are presented as the mean ± SEM (n ¼ 8 per
group). *P < 0.05, **P < 0.01 vs. control group; #P < 0.05, ##P < 0.01 vs. H/R group.
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compared with the H/R group (P < 0.05; n ¼ 8). The response of
artery rings from the ACh-treated group without H/R induction to
ACh was similar to that of the control group. The pD2 values for the
control, H/R, ACh, and ACh þ H/R groups were 7.25 ± 0.11,
6.85 ± 0.14, 7.34 ± 0.11, and 6.89 ± 0.11, respectively, and there was
no signiﬁcant difference in the pD2 values between any of the
groups. We also observed no signiﬁcant differences in the vasodi-
latation response to the exogenous nitric oxide (NO) donor SNP
between the control, H/R, and ACh-pretreatment groups (Fig. 4B).
3.4. Effect of ACh pretreatment on calcium-sensing receptor
expression
We determined the effects of ACh on CaSR expression in
mesenteric arteries using RT-PCR and Western blotting. H/R
signiﬁcantly increased the expression of CaSR mRNA and protein
phosphorylation levels; however, the total protein level did not
change signiﬁcantly. Additionally, ACh pretreatment signiﬁcantly
inhibited the H/R-induced upregulation of CaSR mRNA expression
and activity. CaSR mRNA and phospho-CaSR protein levels in the
ACh group were comparable to those in the control group (Fig. 5).
3.5. ACh pretreatment affects vascular dysfunction injury by
inhibiting CaSR in mesenteric artery rings exposed to H/R
We next examined the effects of the CaSR antagonist NPS2143
on the concentration-response curves for KCl, PE and ACh in
mesenteric artery rings exposed to H/R. The artery rings were
pretreated with NPS2143 (10 mmol/L) for 30 min. The
concentration-response curves for KCl and PE were shifted to the
right in all artery rings in the NPS2143-pretreatment groupcompared with the H/R group. The Emax value induced by KCl was
signiﬁcantly lower in the NPS2143 treatment group compared with
the H/R group (101% ± 8.12% vs. the H/R group, P < 0.05; n ¼ 8;
Fig. 6A). The Emax value induced by PE was 101% ± 12.7%, which was
not signiﬁcantly different compared with that in the H/R group
(P > 0.05; n ¼ 8; Fig. 6B). The pD2 values (1.58 ± 0.06 for KCl and
6.68 ± 0.24 for PE) in the NPS2143-pretreatment group were
remarkably lower than those in the H/R group (P < 0.01, P < 0.05;
n ¼ 8). However, the endothelium-dependent vasodilator re-
sponses to ACh were not reduced in the NPS2143-pretreatment
group compared with the H/R group; the Emax value was
66% ± 7.58% (P > 0.05; n ¼ 8; Fig. 6C).
Next, CaCl2 (106e103 mol/L) was used to produce a
concentration-dependent contraction in depolarized mesenteric
artery rings in Ca2þ-free Krebs solution (0.5 mmol/L EGTA instead
of CaCl2). The Emax values of the CaCl2-induced contraction curves
for the H/R group (138% ± 11%) were signiﬁcantly higher than those
in the control group (91% ± 10%, P < 0.05; n ¼ 8). ACh pretreatment
markedly decreased the Emax values (108% ± 9%, P < 0.05; n ¼ 8)
compared with those in the H/R group. The maximum contractile
response to CaCl2 was not affected by ACh in the untreated control
group (99% ± 6% vs. the control group; P > 0.05; n ¼ 8; Fig. 6D). The
pD2 values in the control, H/R, ACh, and ACh-pretreatment groups
were 4.73 ± 0.08, 4.77 ± 0.10, 4.64 ± 0.08, and 4.64 ± 0.06,
respectively. There were no signiﬁcant differences between the
groups. Next, we observed that the vasoconstriction of the H/R
group was abolished by NPS2143 (Emax: 95% ± 10%; pD2:
4.68 ± 0.12; Fig. 6E). To further evaluate the protective effects of
ACh that may be related to CaSR, we used R568 (an agonist of CaSR,
1 mmol/L). ACh signiﬁcantly shifted the CaCl2-induced contraction
curves to the right, and the Emax and pD2 values in the ACh-
pretreated groups (112% ± 5% and 4.67 ± 0.06, respectively;
Fig. 3. Effects of ACh on (A) KCl- and (B) PE-induced contractioneresponse curves of
rat mesenteric arterial rings. The concentration curves obtained from the control
group, H/R group, ACh-treated control group, and ACh-treated H/R group are shown.
The values are the mean ± SEM (n ¼ 8 per group). *P < 0.05, **P < 0.01 vs. control
group; #P < 0.05 vs. H/R group.
Fig. 4. Effects of ACh on (A) ACh- and (B) SNP-induced relaxationeresponse curves of
rat mesenteric arterial rings. The concentration curves obtained from the control, H/R,
ACh-treated control, and ACh-treated H/R groups are shown. The values are the
mean ± SEM (n ¼ 8 per group). *P < 0.05, **P < 0.01 vs. control group; #P < 0.05 vs. H/R
group.
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treatment groups (130% ± 7% and 5.31 ± 0.06, respectively; P< 0.05,
P < 0.01; n ¼ 8; Fig. 6F). These results indicated that the beneﬁcial
effects of ACh may be related to the inhibition of H/R-induced CaSR
activation.
4. Discussion
CaSR is widely expressed in the vascular system, and it plays an
important role in regulating vascular tone (14). The present study
used an improved ‘ischemia mimetic’ solution and a hypoxic
environment to mimic the vascular damage of in vivo I/R. The re-
sults showed that H/R enhanced the contractility of mesenteric
arteries, impaired endothelial function, and increased CaSR mRNA
and protein expression. The CaSR antagonist NPS2143 signiﬁcantly
inhibited the vasoconstriction induced by KCl, PE and CaCl2 in H/R
mesenteric arteries and did not enhance the vasodilation induced
by ACh, indicating that inhibition of CaSR is one factor contributing
to the effects of ACh. ACh pretreatment ameliorated vascular
dysfunction, inducing contractile responses of the artery that were
remarkably similar to those induced by NPS2143, and signiﬁcantly
suppressed H/R-induced CaSR mRNA and protein expression in
mesenteric arteries. Furthermore, ACh signiﬁcantly attenuated the
CaCl2-induced contractile reaction in mesenteric arteries in the
group treated with CaSR agonist (R568). These results suggest that
ACh exerts a beneﬁcial effect on vascular function, presumably in
part via decreasing CaSR expression and activity, thereby inhibiting
the increase in [Ca2þ]i. Our ﬁndings may be indicative of a novel
mechanism underlying ACh-induced vascular protection.Calcium homeostasis plays an important role in smooth muscle
contraction. Activation of CaSR induced an increase in [Ca2þ]i and
caused constriction of vascular smooth muscle cells (15). The
mechanisms of action of CaSR may involve coupling to Gq/11 pro-
teins and subsequent activation of PLC, leading to IP3R and diac-
ylglycerol (DAG) release (16) or protein kinase C-dependent
activation of TRPC6 channels (17). One of the major clinical mani-
festations of CaSR activationwas an increase in blood pressure (18).
Moreover, Annemarieke et al. observed that the CaSR antagonist
attenuated smooth muscle contractions in response to KCl and PE,
which may be related to changes in interstitial Ca2þ resulting from
intracellular Ca2þ signaling (19). These results suggested that CaSR
speciﬁcally inﬂuenced Ca2þ-dependent contractions. In the present
study, we demonstrated that the CaSR inhibitor NPS2143 could
attenuate H/R-induced vascular contractile reactivity to KCl and PE
in the mesenteric artery; however, NPS2143 could not improve the
endothelium-dependent relaxation that occurs in response to ACh.
A direct relationship between CaSR and Ca2þ-dependent contrac-
tions has been demonstrated by Li et al., who observed that
increasing the extracellular Ca2þ concentration from 5 to
12.5 mmol/L increased vasoconstriction in a dose-dependent
manner and that this vasoconstriction was nearly abolished by
NiCl2, CdCl2, and NPS2390. These results indicated that extracel-
lular Ca2þ-mediated vasoconstriction was at least partially induced
by the activation of CaSR (8). Our observations also showed that the
dose-dependent enhancement of CaCl2-induced constriction was
nearly abolished by NPS2143 in the H/R group. Additionally, we also
detected a marked increase in CaSR mRNA and phosphorylated
protein levels in rat mesenteric arteries after H/R. These results
suggested that the up-regulation of CaSR might be related to H/R-
Fig. 5. Effects of ACh on (A) mRNA expression and (B) protein expression of CaSR. Values are the mean ± SEM (n ¼ 8 per group). *P < 0.05, **P < 0.01 vs. control group; #P < 0.05 vs.
H/R group.
M. Zhao et al. / Journal of Pharmacological Sciences 127 (2015) 481e488486induced vascular smooth muscle cell injury. Increasing evidence
indicates that CaSR expression and function are both enhanced in
various diseases such as vascular calciﬁcation, arteriosclerosis, hy-
pertension and idiopathic pulmonary arterial hypertension (20).
Yamamura et al. reported that the expression and function of CaSR
were both signiﬁcantly enhanced in the pulmonary arteries of rats
and mice with pulmonary hypertension (21).
Autonomic dysfunction during cardiovascular diseases has
serious clinical consequences; thus, improvement of vagus nerve
tone may be a new therapeutic target for cardiovascular diseases,
including I/R injury (22). However, most previous studies have
shown that these beneﬁcial effects can be found in theFig. 6. Effect of CaSR on vascular contractions of rat mesenteric arterial rings exposed to
NPS2143 on PE-induced contractioneresponse curves. (C) Effect of NPS2143 on ACh-indu
tractions in the H/R group. (E) Effect of NPS2143 on contraction in the H/R group. (F) Effect o
*P < 0.05 vs. control group; #P < 0.05 vs. H/R group; &&P < 0.01, &P < 0.05 vs. R568 group.myocardium, while the role of the vagus nerve in the artery is not
clear. In fact, nicotinic andmuscarinic ACh receptors have also been
identiﬁed in many cell types, including endothelial cells and
vascular smooth muscle cells (23,24). Our recent studies have
demonstrated that vagus nerve stimulation (VNS) not only reduces
infarct size and improves cardiac function but also ameliorates
regional cardiac I/R-induced endothelial dysfunction in mesenteric
arteries (13).
ACh, the major neurotransmitter of the vagus nerve, acts on
both muscarinic and nicotinic receptors to exert its effects. ACh
causes endothelium-dependent dilation by activating endothelial
nitric oxide synthase and increasing NO generation (25). AChH/R. (A) Effect of NPS2143 on KCl-induced contractioneresponse curves. (B) Effect of
ced relaxationeresponse curves. (D) Effect of ACh on intracellular Ca2þ-induced con-
f ACh on contraction in the R568 group. Values are the mean ± SEM (n ¼ 8 per group).
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variety of arteries in animal models, and inhibitors of NO synthase
have been shown to abolish the protective effects of ACh in rats
(26,27). In the present study, ACh had a dose-dependent protective
effect on arteries exposed to H/R, and 106 mol/L ACh signiﬁcantly
improved vascular vasoconstriction and endothelium-dependent
vasodilatation in arteries exposed to H/R. Importantly, according
to our experimental results, the abnormal endothelium-dependent
vascular relaxation induced byH/R was not involve CaSR, indicating
that inhibition of CaSR is not the only factor contributing to the
effects of ACh (Fig. 6C). Thus, we speculate that the ACh-induced
enhancement of endothelial-dependent dilation of arteries
exposed to H/R may be mediated by NO. Recent studies have
demonstrated that ACh could activate the AMP-activated protein
kinase pathway to attenuate vasoconstriction in endothelium-
denuded rat aortas (28). The recently identiﬁed vascular effect of
ACh has become a topic of great interest. In this study, we observed
a signiﬁcant decrease in CaSR mRNA expression and CaSR phos-
phorylation levels after ACh intervention in the H/R group. ACh also
signiﬁcantly suppressed the vasoconstriction induced by CaCl2 in
the group treated with a CaSR activator (R568). These results sug-
gest that ACh-induced vascular protection was partially related to
the inhibition of CaSR.
Notably, we applied an in vitro organ culture system with
modiﬁed ‘ischemia mimetic’ solution and an anaerobic environ-
ment to mimic I/R injury. Ischemia may lead to metabolic abnor-
malities by inhibiting aerobic oxidation and the energy supply via
lactate accumulation, depletion of ATP, and acidiﬁcation of the
extracellular environment (29). Extensive evidence has suggested
that the simple H/R model used to investigate in vitro vascular
function is disputable, and to date, only a few functional studies
have investigated in vitro vascular H/R (30). Radovits et al. raised
serious concerns regarding the reliability of the in vitro H/R model,
and they demonstrated that endothelial injury occurring in vessel
rings during simple in vitro H/R was too insigniﬁcant to be
demonstrated in functional measurements (31). Conventional
‘ischemia mimetic’ solutions include some key components for
inducing glucose deﬁciency, hypoxia, hyperosmosis, lactate accu-
mulation, and acidosis. Our studies also demonstrated that modi-
ﬁed ‘ischemia mimetic’ solution could be used to mimic acidosis
and the extracellular environment during tissue ischemic injury
(32). In this study, the modiﬁed ‘ischemia mimetic’ solution, com-
bined with hypoxia, was utilized to simulate ischemic insult in
cultured vessels.
In conclusion, activation of CaSR has been linked to increased
cytosolic Ca2þ levels, triggering dysfunctional vasoconstriction af-
ter H/R. Our data suggest that ACh was able to ameliorate vascular
dysfunction in mesenteric arteries exposed to H/R, presumably in
part by inhibiting CaSR expression after H/R. We also showed that
ACh signiﬁcantly attenuated the vasoconstriction of mesenteric
arteries in the group treated with the CaSR agonist R568, further
demonstrating the beneﬁcial role of ACh. Our results provide a
novel explanation for the salutary effects of ACh in regulation of the
vasculature. Therefore, activation of the vagus nerve could be an
alternative therapeutic strategy for preventing vascular injury
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